Today: 23 May 2026
Mastercard stock in focus for Monday after Trump floats 10% credit-card rate cap
10 January 2026
1 min read

Mastercard stock in focus for Monday after Trump floats 10% credit-card rate cap

NEW YORK, Jan 10, 2026, 05:51 EST — The market has closed.

  • Mastercard (NYSE:MA) closed Friday 0.8% lower, at $575.54.
  • Starting Jan. 20, Trump proposed a one-year cap on credit card interest rates set at 10%.
  • Upcoming on investors’ radar: U.S. CPI data due Jan. 13 and the Fed meeting set for Jan. 27-28. Mastercard is slated to report earnings on Jan. 29.

Mastercard Incorporated shares enter Monday trading with credit policy in focus, following President Donald Trump’s call to cap credit card interest rates at 10% for one year starting Jan. 20. The stock closed down Friday, despite the broader market hitting new highs.

The proposal focuses on card issuers rather than payment networks such as Mastercard, though traders frequently treat the sector as a whole. If the cap tightens credit availability, it could dampen card spending and curb loan growth — eventually weighing on transaction volumes.

Timing is everything. Payments stocks now serve as a quick gauge of both the U.S. consumer and interest rate trends. The coming weeks are packed with inflation reports, Fed announcements, and earnings releases.

U.S. stocks hit record highs on Friday following a weaker-than-anticipated December jobs report showing a 50,000 payroll increase and a 4.4% unemployment rate, Reuters said. The S&P 500 climbed 0.65%, even as Mastercard slipped, Visa edged down 0.7%, and American Express fell 1.9%.

Friday was the record date for Mastercard’s upcoming quarterly dividend of $0.87 a share, with payment scheduled for Feb. 9, per the company’s dividend calendar. Stocks often dip around this cut-off since new investors miss out on the payout.

Sell-side price targets remain firmly above Mastercard’s last close. MarketWatch-tracked analysts put the average target at $664.32, with forecasts spanning from $525 up to $745. The stock has traded between $465.59 and $601.77 over the past year, currently sitting about 4% shy of its high.

There’s movement on the company-specific front as well. JPMorgan and Apple announced this week that JPMorgan will take over the Apple Card portfolio from Goldman Sachs, with Mastercard continuing as the payment network; the deal isn’t expected to close for about two years. Goldman CEO David Solomon described it as a deal that “substantially completes” the bank’s shift away from consumer banking.

The consumer outlook isn’t straightforward. The University of Michigan’s early-January sentiment index nudged up to 54.0 from 52.9, yet director Joanne Hsu noted households “remain guarded” on business conditions and the labor market. A New York Fed survey found Americans grew more concerned about job prospects in December, even as its president John Williams said inflation expectations “remain well-anchored.”

This story could still fall apart in several ways. Trump’s call for a rate cap came without any concrete plan and would probably require Congress to act. Industry groups have warned such a cap might “reduce credit availability,” hitting payments volumes. On top of that, Mastercard and Visa are under continued scrutiny over their card fees; last month, major retailers pushed a judge to reject a proposed swipe-fee settlement. Reuters

Stock Market Today

  • UBS Boosts Jazz Pharma Stock Price Target to $307 Ahead of FDA Decision
    May 23, 2026, 2:29 PM EDT. UBS upgraded Jazz Pharmaceuticals (JAZZ) stock from neutral to buy, raising its price target by 63% to $307 from $188. This surge exceeds the prior consensus of $242 and follows strong Q1 results, with revenue up 19% year-over-year and oncology portfolio growth of 45%. The move anticipates FDA approval on August 25 of Zanidatamab (Ziihera) for HER2-positive gastroesophageal cancer, expected to generate peak sales of $3.1 billion. UBS projects 10% revenue and 11% earnings growth from 2026-2030, versus consensus of around 7% and 6%, and supports a valuation multiple increase from 7x to 10x earnings, reflecting confidence in sustainable growth. Key risks include FDA delays, slower oncology sales ramp, and underperformance of core franchises like Xywav and Epidiolex.

Latest articles

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

AbbVie Shares Edge Up Ahead Of Holiday On Pipeline News

23 May 2026
AbbVie shares closed Friday at $215.70, up 0.56%, gaining 2.5% for the week. The company reported a positive European panel recommendation for MAVIRET in acute hepatitis C and released new oncology data ahead of the ASCO meeting. U.S. markets are closed Monday for Memorial Day, with trading set to resume Tuesday.
Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

Coherent Shares Trade Close to $378, With Next Test Set for Tuesday After Volatile AI-Optics Week

23 May 2026
Coherent Corp. shares closed at $377.57 Friday, down 0.1% for the day and 1.3% below last week, underperforming the S&P 500 and Nasdaq ahead of the Memorial Day market closure. The company reported fiscal Q3 revenue of $1.81 billion, up 21% year-over-year, with strong demand in datacenter and communications. Nvidia invested $2 billion in March and signed a multi-year optics agreement. Coherent trades at 179 times trailing earnings.
Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

Intuit Slashes 3,000 Jobs as TurboTax Faces New AI Threats

23 May 2026
Intuit will cut about 3,000 jobs, or 17% of its workforce, and close offices in Reno and Woodland Hills as it restructures to focus on artificial intelligence. The company expects $300 million to $340 million in charges, mostly in the fiscal fourth quarter. Intuit raised full-year revenue guidance but lowered its TurboTax outlook, citing pressure from low-cost AI tools. Shares last traded at $319.94 after a volatile week.
Haleon PLC stock slides on operating model shake-up as investors look to Feb. 25 results
Previous Story

Haleon PLC stock slides on operating model shake-up as investors look to Feb. 25 results

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy
Next Story

Kenvue stock countdown: Jan. 29 merger vote looms as KVUE deal spread stays jumpy

Go toTop